FOLH1 and prostate cancer: A similar approach is to engineer a dominant-negative TGF-βRII (dnTGF-βRII) to decrease TGF-β availability and block its signaling within PSMA targeting CAR-T cells for the treatment of TGF-β secreting prostate cancer [95].